Abstract
Worldwide ~235 million people currently suffer from asthma. We searched the integrative medicine and the ancient cultures in the Middle East, Africa, and China for new anti-asthma treatment. LE25-0712 is an herbal extract (formula under patent). Here, we used it to validate the old knowledge known, to treat acute allergic asthma mice model. We also identify the effect of our novel extract on the expression of AMs-HDAC1 (alveolar macrophages-histone deacetylase1). We had proven in a previous study, deletion of HDAC1 had increased allergic airway inflammation and enhanced Th2 cytokine production in asthma mice model. In asthmatic and COPD patients, PBMC-HDAC level was reduced compared to healthy individual. In this study, we evaluated the effect of LE25-0712 on the expression level of AMs-HDAC1 in treated asthmatic mice (TAM) model compared to asthmatic control (AC) group.
Highlights
Worldwide ~235 million people currently suffer from asthma
We identify the effect of our novel extract on the expression of AMs-HDAC1
We evaluated the effect of LE25-0712 on the expression level of AMs-HDAC1 in treated asthmatic mice (TAM) model compared to asthmatic control (AC) group
Summary
Restoring AMs-HDAC1 expression in allergic asthma mice model by novel medicinal plant. We searched the integrative medicine and the ancient cultures in the Middle East, Africa, and China for new anti-asthma treatment. LE25-0712 is an herbal extract (formula under patent). We used it to validate the old knowledge known, to treat acute allergic asthma mice model. We identify the effect of our novel extract on the expression of AMs-HDAC1 (alveolar macrophageshistone deacetylase). We had proven in a previous study, deletion of HDAC1 had increased allergic airway inflammation and enhanced Th2 cytokine production in asthma mice model. We evaluated the effect of LE25-0712 on the expression level of AMs-HDAC1 in treated asthmatic mice (TAM) model compared to asthmatic control (AC) group
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
